7 Analysts Assess Viridian Therapeutics: What You Need To Know
Portfolio Pulse from Benzinga Insights
7 analysts have provided mixed ratings for Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, with a range of opinions from bullish to bearish. The average 12-month price target has declined by 15.38% to $26.57. Analysts have adjusted their ratings and price targets in response to market conditions and company performance.
June 06, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed ratings on Viridian Therapeutics, with a recent decline in the average 12-month price target by 15.38% to $26.57. The ratings range from bullish to bearish, reflecting varied sentiments on the company's future performance.
The mixed ratings and the decline in the average price target indicate uncertainty among analysts about Viridian Therapeutics' future performance. This could lead to neutral short-term price movements as investors digest the varied opinions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100